Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Modern Chinese Medicine Group Co., Ltd.
現代中藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1643)

INSIDE INFORMATION
DISPOSAL OF SHARES BY A CONTROLLING SHAREHOLDER
AND
RESUMPTION OF TRADING

This announcement is made by the board (the "**Board**") of directors (the "**Director(s)**") of Modern Chinese Medicine Group Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**" and the "**Stock Exchange**" respectively) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As confirmed by Ms. Sun Xinlei ("**Ms. Sun**"), the chairlady of the Board and an executive Director, on 26 November 2026, a securities broker placed a total of 144,000,000 shares of the Company to a number of placees (the "**Disposal**") on behalf of Modern Biotechnology Group Holdings Co., Ltd. ("**Modern Biotechnology**") at a share price of HK$0.217 per share. Modern Biotechnology is a controlling shareholder of the Company and is wholly owned by Ms. Sun. The Disposal was made on the account of Ms. Sun's personal financial arrangement.

Immediately before the Disposal, Modern Biotechnology was interested in 402,000,000 shares of the Company, representing approximately 55.8% of the total issued shares of the Company. Immediately after the Disposal, the shareholding of Modern Biotechnology in the Company has been dropped to approximately 35.8%, represented by 258,000,000 shares of the Company.

The Company does not expect that the Disposal will have any material adverse effect on the business operation and financial position of the Group.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

RESUMPTION OF TRADING

Pending the release of this announcement, trading in the shares of the Company has been halted with effect from 11:18 a.m. Thursday, 26 November 2026. An application has been made by the Company to the Stock Exchange for resumption of trading in the shares of the Company with effect from 9:00 a.m. on Friday, 27 November 2026.

By Order of the Board
Modern Chinese Medicine Group Co., Ltd.
Zhang Hongli
Executive Director

Hong Kong, 26 November 2026

As at the date of this announcement, the board of the Company comprises three executive directors, namely Ms. Sun Xinlei, Ms. Zhang Hongli and Ms. Jia Yanru; and three independent non-executive directors, namely Ms. Liu Ling, Mr. Leung Tsz Wing and Mr. Wong Chi Kin.